Linked Life Data

7749761

Source:http://linkedlifedata.com/resource/pubmed/id/7749761

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1995-6-20
pubmed:abstractText
Techniques to assay minimal residual disease are available for most patients with acute lymphoblastic leukemia, non-Hodgkin's lymphoma, breast cancer, Ewing's sarcoma, and others. Today, a few such tests exist for acute myelogenous leukemia (AML). This review evaluates the tests available for assessing minimal residual disease in AML: morphology, growth in vitro, cytogenetics, magnetic resonance imaging, polymerase chain reaction (PCR)-based assays for translocation products, and multiparameter flow cytometry. Of these, multiparameter flow cytometry appears most promising. Studies using multiparameter flow cytometry to identify leukemic cells by aberrant antigen expression have reported a high positive predictive value with regard to the incidence of relapse. In addition, the test is specific, rapid, inexpensive, and applicable to a sufficiently broad group of patients, allowing its use outside of the research laboratory setting. Judicious use of some of the available assays singly or in combination should identify patients harboring residual leukemic cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1077-4114
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:geneSymbol
bcr-abl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
123-33
pubmed:dateRevised
2011-10-6
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Detection of minimal residual disease in acute myelogenous leukemia.
pubmed:affiliation
Fred Hutchinson Cancer Research Center, Department of Pediatric Oncology, Seattle, WA 98104, USA.
pubmed:publicationType
Journal Article, Review